|
KMID : 1143420220150040217
|
|
Public Health Weekly Report
2022 Volume.15 No. 4 p.217 ~ p.224
|
|
|
Adverse events following COVID-19 vaccination in adolescents aged 12-17 years
|
|
Kim Seon-Tae
Ko Mi-Jeong
Kim Hyung-Jun
Park Kyeong-Eun
Cho Sang-Yun
Lee Yeon-Kyeng
Kwon Yun-Hyung
Hwang In-Sob
|
|
|
Abstract
|
|
|
In the Republic of Korea (ROK), adolescents aged between 12 and 17 years first started to be vaccinated with the Pfizer
vaccine on October 19, 2021. Considering that unexpected adverse events (AEs) may occur after vaccination and to identify AEs at an early stage after vaccination, an AEs reporting system based on the Korea Immunization Management System (KIMS) and monitoring through text message questionnaires were implemented. Following our previous report, “Adverse events following COVID-19 vaccination in adolescents aged 16?17 years”, we analyzed the data of AEs reported between October 18, 2021, and November 20, 2021, for adolescents, including those aged 12?15 years who received the first vaccine dose and the results of a survey regarding AEs and health status on the initial vaccination day and up to 7 days after vaccination. During this period, 2,834 AEs were reported through KIMS and the reported rate was 0.26% compared to the number of doses administered. The reported rates by age group were 0.16% in aged 12?15 years and 0.34% in aged 16?17 years. Among reported AEs, non-serious AEs such as headache, chest pain, dizziness, and myalgia accounted for 97.78% of cases, while serious AEs such as suspected anaphylaxis and major AEs accounted for 2.22% of cases. A total of 11,601 adolescents responded to the text message questionnaire, among whom 53.93% of 12?15-year-olds reported at least one health problem or AE from 0 to 7 days after the first dose of the Pfizer vaccine. The response rate was slightly higher in adolescents aged 16?17 years at 57.56%. Systemic AEs were reported by 44.12% of 12?15 years old and 50.42% of 16?17 years old. The types of AEs were injection site pain, myalgia, fatigue/tiredness, and headache.
This study is an initial analysis of AEs after the first dose of the Pfizer vaccine for coronavirus disease 2019 (COVID-19) in
adolescents aged 12?17 years in the ROK. In order to promote a safe COVID-19 vaccination program, the Korea Disease
Control and Prevention Agency (KDCA) will continue to monitor AEs and share the information with relevant committees and experts.
|
|
|
KEYWORD
|
|
|
COVID-19 vaccination, Adolescents aged 12-17 years, Adverse events
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|